BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 31165040)

  • 1. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
    Ng K; Metcalf R; Sacco J; Kong A; Wheeler G; Forsyth S; Bhat R; Ward J; Ensell L; Lowe H; Spanswick V; Hartley J; White L; Lloyd-Dehler E; Forster M
    BMJ Open; 2023 Nov; 13(11):e070391. PubMed ID: 38011968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
    Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).
    Bonomo P; Desideri I; Loi M; Mangoni M; Sottili M; Marrazzo L; Talamonti C; Greto D; Pallotta S; Livi L
    Clin Transl Radiat Oncol; 2018 Feb; 9():42-47. PubMed ID: 29594250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Immunotherapy in Head and Neck Cancer.
    Ling DC; Bakkenist CJ; Ferris RL; Clump DA
    Semin Radiat Oncol; 2018 Jan; 28(1):12-16. PubMed ID: 29173750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for head and neck cancer: Recent advances and future directions.
    Cramer JD; Burtness B; Ferris RL
    Oral Oncol; 2019 Dec; 99():104460. PubMed ID: 31683169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
    Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists.
    Xing DT; Khor R; Gan H; Wada M; Ermongkonchai T; Ng SP
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
    Zech HB; Laban S; Schafhausen P; Bussmann L; Betz C; Busch CJ
    HNO; 2019 Dec; 67(12):898-904. PubMed ID: 31701170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer.
    Tathineni P; Joshi N; Jelinek MJ
    Curr Treat Options Oncol; 2023 Jun; 24(6):680-692. PubMed ID: 37067660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
    Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
    J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib in squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.